ABSTRACT
Children with CKD stages 2 to 5 and 5D should be evaluated at least twice as frequently as same-aged healthy children, with more frequent monitoring to be done in infants as well as patients with comorbidities such as cachexia, protein-energy wasting, and growth failure.
